EPM speaks to Paul Burden, chief commercial officer – Strategic Growth, at ADVANZ PHARMA about niche medicines, the challenges of working with multiple partners and why competition is everywhere in pharma.
Meet the maker
First of all could you please introduce yourself and your role at ADVANZ PHARMA?
My name is Paul Burden, chief commercial officer – Strategic Growth, at ADVANZ PHARMA. This means I am responsible for the performance of our Strategic Growth Business unit. This includes a large, well established off-patent business in the UK & Ireland through which we provide approximately 40 million packs into the NHS, but also a growing Specialty Brands Business in Europe which has expertise in cardiovascular and anti-infectives, providing us with a strong platform through which to access hospital markets across Europe.
Additionally I have responsibility for our Corporate Communications, including IR and PR.